Profile data is unavailable for this security.
About the company
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on development products and technologies to combat various diseases. The Company develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. It has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, and ABV-1703. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). It is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy. Its ABV-1519 is used for the treatment of non-small cell lung cancer. ABV-1703 is a drug for advanced, inoperable, or metastatic pancreatic cancer. The Company develops drugs and medical devices derived from plants.
- Revenue in USD (TTM)509.80k
- Net income in USD-8.24m
- Incorporated2002
- Employees16.00
- LocationABVC Biopharma Inc44370 Old Warm Springs BlvdFREMONT 94538-6148United StatesUSA
- Phone+1 (510) 668-0881
- Websitehttps://abvcpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ensysce Biosciences Inc | 4.42m | -7.93m | 6.41m | 7.00 | -- | 0.9614 | -- | 1.45 | -2.04 | -2.04 | 0.6545 | 0.498 | 0.7016 | -- | 4.68 | 631,628.60 | -125.79 | -17.68 | -188.13 | -19.42 | -- | -- | -179.29 | -715.78 | -- | -3.88 | 0.0556 | -- | -11.61 | -- | 57.64 | -- | -- | -- |
| Ainos Inc | 40.63k | -16.13m | 6.45m | 46.00 | -- | 0.3459 | -- | 158.69 | -2.77 | -2.77 | 0.0058 | 1.30 | 0.0013 | 0.9734 | 507.88 | 883.26 | -49.47 | -36.36 | -53.53 | -58.33 | -352.82 | 36.82 | -39,708.71 | -813.63 | 1.33 | -30.90 | 0.405 | -- | -96.53 | 9.46 | 1.69 | -- | 66.44 | -- |
| Adial Pharmaceuticals Inc | 0.00 | -13.03m | 6.47m | 4.00 | -- | 1.10 | -- | -- | -4.49 | -4.50 | 0.00 | 0.9185 | 0.00 | -- | -- | 0.00 | -272.04 | -182.35 | -316.95 | -235.45 | -- | -- | -- | -- | -- | -16.22 | 0.00 | -- | -- | -- | 35.14 | -- | -- | -- |
| Transcode Therapeutics Inc | 0.00 | -14.93m | 6.64m | 10.00 | -- | 3.59 | -- | -- | -8.49 | -8.49 | 0.00 | 0.0957 | 0.00 | -- | -- | 0.00 | -210.77 | -133.14 | -475.23 | -181.26 | -- | -- | -- | -- | -- | -40.02 | 0.00 | -- | -- | -- | -5.59 | -- | -- | -- |
| Virpax Pharmaceuticals Inc | 0.00 | -13.24m | 6.64m | 7.00 | -- | -- | -- | -- | -8.82 | -8.82 | 0.00 | -0.4198 | 0.00 | -- | -- | 0.00 | -198.45 | -87.52 | -594.46 | -116.56 | -- | -- | -- | -- | -- | -128.86 | -- | -- | -- | -- | 29.84 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -14.23m | 6.64m | 29.00 | -- | -- | -- | -- | -3.46 | -3.46 | 0.00 | -1.14 | 0.00 | -- | -- | 0.00 | -369.22 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -35.87 | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
| NLS Pharmaceutics AG | 0.00 | -6.60m | 6.79m | 3.00 | -- | -- | -- | -- | -6.72 | -6.72 | 0.00 | -9.40 | 0.00 | -- | -- | 0.00 | -380.82 | -272.62 | -- | -- | -- | -- | -- | -- | -- | -27.20 | -- | -- | -- | -- | 26.21 | -- | -- | -- |
| National Graphite Corp | 0.00 | -1.97m | 6.79m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
| Intelligent Bio Solutions Inc | 3.19m | -10.42m | 6.80m | 13.00 | -- | 1.08 | -- | 2.13 | -27.94 | -27.94 | 1.42 | 1.39 | 0.3121 | 1.93 | 5.56 | 245,228.50 | -102.35 | -71.59 | -255.70 | -144.36 | 48.31 | -- | -327.90 | -565.48 | 1.01 | -- | 0.0775 | -- | 147.58 | 596.39 | 4.47 | -- | -- | -- |
| Plus Therapeutics Inc (USA) | 5.73m | -12.89m | 6.96m | 20.00 | -- | -- | -- | 1.22 | -2.42 | -2.42 | 0.988 | -0.8775 | 0.5653 | -- | -- | 286,250.00 | -127.22 | -59.18 | -- | -133.04 | -- | -- | -225.07 | -470.45 | -- | -4.31 | -- | -- | 2,093.30 | -5.89 | 34.32 | -- | 3.77 | -- |
| Edesa Biotech Inc | 0.00 | -6.93m | 7.05m | 16.00 | -- | 2.44 | -- | -- | -2.21 | -2.21 | 0.00 | 0.8829 | 0.00 | -- | -- | 0.00 | -94.60 | -- | -128.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.28 | -- | -- | -- |
| ABVC Biopharma Inc | 509.80k | -8.24m | 7.12m | 16.00 | -- | 0.7938 | -- | 13.97 | -0.9744 | -0.9744 | 0.0508 | 0.6576 | 0.0328 | -- | 1.60 | 31,862.50 | -56.14 | -103.38 | -88.09 | -231.54 | 72.54 | 76.25 | -1,710.03 | -2,019.89 | -- | -2.62 | 0.1856 | -- | -84.28 | 85.39 | 35.97 | -- | -- | -- |
| Mosaic Immunoengineering Inc | 0.00 | -1.06m | 7.24m | 3.00 | -- | -- | -- | -- | -0.1471 | -0.1471 | 0.00 | -0.9162 | 0.00 | -- | -- | 0.00 | -654.11 | -- | -- | -- | -- | -- | -- | -- | -- | -12.50 | -- | -- | -- | -- | 57.65 | -- | -- | -- |
| Biora Therapeutics Inc | 892.00k | -35.57m | 7.25m | 58.00 | -- | -- | -- | 8.12 | -12.92 | -11.78 | 0.2163 | -28.99 | 0.0363 | -- | 1.06 | 15,379.31 | -144.59 | -122.84 | -- | -369.01 | -- | -- | -3,988.12 | -415.10 | -- | -- | -- | -- | -98.69 | -87.44 | -154.63 | -- | -53.68 | -- |
| Galecto Inc | 0.00 | -21.17m | 7.40m | 13.00 | -- | 0.3432 | -- | -- | -19.33 | -19.33 | 0.00 | 16.70 | 0.00 | -- | -- | 0.00 | -57.67 | -48.46 | -72.47 | -52.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.77 | -- | -- | -- |
Data as of Nov 25 2024. Currency figures normalised to ABVC Biopharma Inc's reporting currency: US Dollar USD
1.84%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Geode Capital Management LLCas of 30 Sep 2024 | 71.61k | 0.58% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 46.95k | 0.38% |
| Avantax Planning Partners, Inc.as of 30 Sep 2024 | 39.00k | 0.31% |
| XTX Markets LLCas of 30 Sep 2024 | 23.41k | 0.19% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 19.14k | 0.15% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 12.90k | 0.10% |
| Two Sigma Securities LLCas of 30 Sep 2024 | 12.40k | 0.10% |
| Tower Research Capital LLCas of 30 Sep 2024 | 2.62k | 0.02% |
| Spotlight Asset Group, Inc.as of 30 Jun 2024 | 100.00 | 0.00% |
| Bank of America, NA (Private Banking)as of 30 Sep 2024 | 78.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
